Genome engineering with TAL-effector nucleases and alternative modular nuclease technologies

Current Gene Therapy

Volumn 13, Issue 4, 2013, Pages 291-303

  Scharenberg, Andrew M ^a,b   Duchateau, Philippe ^a   Smith, Julianne ^a  

^a Arvid Wallgrens Backe 20   (France)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

DNA repair; Double strand break; Exonuclease; Genome engineering; Homing endonuclease; Meganuclease; Nuclease; TALEN; ZFN; Zinc finger nuclease

Indexed keywords

DNA BINDING PROTEIN; ENDONUCLEASE I TEVI; MEGANUCLEASE; NUCLEASE; PEPTIDES AND PROTEINS; POLYPEPTIDE; RAD52 PROTEIN; RNA GUIDED ENDONUCLEASE; TAL EFFECTOR NUCLEASE; TRACKING PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER NUCLEASE;

ARTICLE; BINDING AFFINITY; DNA END JOINING REPAIR; DNA STRAND BREAKAGE; DNA TEMPLATE; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVITY; ENZYME SPECIFICITY; GENETIC ENGINEERING; GENETIC TRANSFECTION; GENOME; HOMOLOGOUS RECOMBINATION; HUMAN; MUTAGENIC ACTIVITY; NONHUMAN; PLASMID; RECOMBINATION REPAIR; VIRAL GENE DELIVERY SYSTEM; XANTHOMONAS;

CASPASE 9; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; GENETIC ENGINEERING; GENETIC THERAPY; HUMANS; PROTEIN ENGINEERING;

EID: 84888107953     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/15665232113139990026     Document Type: Article

References (102)

1. Carroll D. Zinc-finger nucleases: a panoramic view. Curr Gene Ther 201111(1):2-10.
2. Carroll D. Genome engineering with zinc-finger nucleases. Genetics 2011;188(4): 773-82.
3. Händel E-M, Cathomen T. Zinc-finger nuclease based genome surgery: it's all about specificity. Curr Gene Ther 2011; 11(1):28-37.
4. Silva G, Poirot L, Galetto R, et al. Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr Gene Ther 2011; 11(1):11-27.
5. Bogdanove AJ, Voytas DF. TAL effectors: customizable proteins for DNA targeting. Science 2011; 333(6051):1843-6.
6. Beurdeley M, Bietz F, Li J, et al. Compact designer TALENs for efficient genome engineering. Nat Commun 2013; 4:1762.
7. Cermak T, Doyle EL, Christian M, et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 2011; 39(12):e82.
8. Sakuma T, Hosoi S, Woltjen K, et al. Efficient TALEN construction and evaluation methods for human cell and animal applications. Genes Cells Devoted Mol Cell Mech 2013; 18(4):315-26.
9. Briggs AW, Rios X, Chari R. Iterative capped assembly: rapid and scalable synthesis of repeat-module DNA such as TAL effectors from individual monomers. Nucleic Acids Res 2012; 40(15):e117.
10. Li T, Yang B. TAL effector nuclease (TALEN) engineering. Methods Mol Biol 2013; 978:63-72.
11. Li T, Huang S, Zhao X, et al. Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes. Nucleic Acids Res 2011; 39(14):6315-25.
12. Doyle EL, Booher NJ, Standage DS, et al. TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction. Nucleic Acids Res 2012; 40(Web Server issue):W117-122.
13. Christian M, Cermak T, Doyle EL, et al. Targeting DNA doublestrand breaks with TAL effector nucleases. Genetics 2010; 186(2):757-61.
14. Schmid-Burgk JL, Schmidt T, Kaiser V, Höning K, Hornung V. A ligation-independent cloning technique for high-throughput assembly of transcription activator-like effector genes. Nat Biotechnol 2013; 31(1):76-81.
15. Mussolino C, Morbitzer R, Lütge F, Dannemann N, Lahaye T, Cathomen T. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res 2011; 39(21):9283-93.
16. Miller JC, Tan S, Qiao G, et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 2011; 29(2):143-8.
17. Reyon D, Khayter C, Regan MR, Joung JK, Sander JD. Engineering designer transcription activator-like effector nucleases (TALENs) by REAL or REAL-Fast assembly. Curr Protoc Mol Biol 2012; Ch 12:Unit 12.15.
18. Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK. FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 2012; 30(5):460-5.
19. Streubel J, Blücher C, Landgraf A, Boch J. TAL effector RVD specificities and efficiencies. Nat Biotechnol 2012; 30(7):593-5.
20. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337(6096):816-21.
21. Hwang WY, Fu Y, Reyon D, et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol 2013; 31(3):227-9.
22. Dicarlo JE, Norville JE, Mali P, Rios X, Aach J, Church GM. Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic Acids Res 2013; 41(7):4336-43.
23. Sternberg SH, Haurwitz RE, Doudna JA. Mechanism of substrate selection by a highly specific CRISPR endoribonuclease. RNA 2012; 18(4):661-72.
24. Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339(6121):819-23.
25. Qi LS, Larson MH, Gilbert LA, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 2013; 152(5):1173-83.
26. Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 2013; 31(3):233-9.
27. Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science 2013; 339(6121):823-6.
28. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. RNA-programmed genome editing in human cells. Elife 2013; 2:e00471.
29. Lee HY, Haurwitz RE, Apffel A, et al. RNA-protein analysis using a conditional CRISPR nuclease. Proc Natl Acad Sci U S A 2013; 110(14):5416-21.
30. Bogdanove AJ, Schornack S, Lahaye T. TAL effectors: finding plant genes for disease and defense. Curr Opin Plant Biol 2010; 13(4):394-401.
31. Boch J, Bonas U. Xanthomonas AvrBs3 family-type III effectors: discovery and function. Annu Rev Phytopathol 2010; 48:419-36.
32. Grant SR, Fisher EJ, Chang JH, Mole BM, Dangl JL. Subterfuge and manipulation: type III effector proteins of phytopathogenic bacteria. Annu Rev Microbiol 2006; 60:425-49.
33. White FF, Potnis N, Jones JB, Koebnik R. The type III effectors of Xanthomonas. Mol Plant Pathol 2009; 10(6):749-66.
34. Alfano JR, Collmer A. Type III secretion system effector proteins: double agents in bacterial disease and plant defense. Annu Rev Phytopathol 2004; 42:385-414.
35. Boch J, Scholze H, Schornack S, et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009; 326(5959):1509-12.
36. Kay S, Hahn S, Marois E, Wieduwild R, Bonas U. Detailed analysis of the DNA recognition motifs of the Xanthomonas type III effectors AvrBs3 and AvrBs3Deltarep16. Plant J 2009; 59(6):859-71.
37. Zhu W, Yang B, Chittoor JM, Johnson LB, White FF. AvrXa10 contains an acidic transcriptional activation domain in the functionally conserved C terminus. Mol Plant Microbe Interact 1998; 11(8):824-32.
38. Kay S, Bonas U. How Xanthomonas type III effectors manipulate the host plant. Curr Opin Microbiol 2009; 12(1):37-43.
39. Szurek B, Marois E, Bonas U, Van den Ackerveken G. Eukaryotic features of the Xanthomonas type III effector AvrBs3: protein domains involved in transcriptional activation and the interaction with nuclear import receptors from pepper. Plant J 2001; 26(5):523-34.
40. Lahaye T, Bonas U. Molecular secrets of bacterial type III effector proteins. Trends Plant Sci 2001; 6(10):479-85.
41. Bonas U, Stall RE, Staskawicz B. Genetic and structural characterization of the avirulence gene avrBs3 from Xanthomonas campestris pv. vesicatoria. Mol Gen Genet 1989; 218(1):127-36.
42. Herbers K, Conrads-Strauch J, Bonas U. Race-specificity of plant resistance to bacterial spot disease determined by repetitive motifs in a bacterial avirulence protein. Nature 1992; 356(6365):172-4.
43. Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by TAL effectors. Science 2009; 326(5959):1501.
44. Deng D, Yan C, Pan X, et al. Structural basis for sequence-specific recognition of DNA by TAL effectors. Science 2012; 335(6069):720-3.
45. Mak AN-S, Bradley P, Bogdanove AJ, Stoddard BL. TAL effectors: function, structure, engineering and applications. Curr Opin Struct Biol 2013; 23(1):93-9.
46. Gao H, Wu X, Chai J, Han Z. Crystal structure of a TALE protein reveals an extended N-terminal DNA binding region. Cell Res 2012; 22(12):1716-20.
47. Grau J, Wolf A, Reschke M, Bonas U, Posch S, Boch J. Computational Predictions Provide Insights into the Biology of TAL Effector Target Sites. Plos Comput Biol 2013; 9(3):e1002962.
48. Scholze H, Boch J. TAL effector-DNA specificity. Virulence 2010; 1(5):428-32.
49. Mak AN-S, Bradley P, Cernadas RA, Bogdanove AJ, Stoddard BL. The crystal structure of TAL effector PthXo1 bound to its DNA target. Science 2012; 335(6069):716-9.
50. Valton J, Dupuy A, Daboussi F, et al. Overcoming transcription activator-like effector (TALE) DNA binding domain sensitivity to cytosine methylation. J Biol Chem 2012; 287(46):38427-32.
51. Römer P, Recht S, Lahaye T. A single plant resistance gene promoter engineered to recognize multiple TAL effectors from disparate pathogens. Proc Natl Acad Sci U S A 2009; 106(48):20526-31.
52. Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 2013; 14(1):49-55.
53. Mussolino C, Cathomen T. TALE nucleases: tailored genome engineering made easy. Curr Opin Biotechnol 2012; 23(5):644-50.
54. Li L, Atef A, Piatek A, et al. Characterization and DNA-Binding Specificities of Ralstonia TAL-like Effectors, Mol Plant 2013; [Epub ahead of print].
55. Mukaihara T, Tamura N. Identification of novel Ralstonia solanacearum type III effector proteins through translocation analysis of hrpB-regulated gene products. Microbiol Read Engl 2009; 155(Pt 7):2235-44.
56. Li T, Huang S, Jiang WZ, et al. TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain. Nucleic Acids Res 2011; 39(1):359-72.
57. Ding Q, Lee Y-K, Schaefer EAK, et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 2013; 12(2):238-51.
58. Doyon Y, Vo TD, Mendel MC, et al. Enhancing zinc-fingernuclease activity with improved obligate heterodimeric architectures. Nat Methods 2011; 8(1):74-9.
59. Boissel S, Jarjour J, Astrakhan A, et al. megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering. (in preparation).
60. Edgell DR, Shub DA. Related homing endonucleases I-BmoI and I-TevI use different strategies to cleave homologous recognition sites. Proc Natl Acad Sci U S A 2001; 98(14):7898-903.
61. Dean AB, Stanger MJ, Dansereau JT, Van Roey P, Derbyshire V, Belfort M. Zinc finger as distance determinant in the flexible linker of intron endonuclease I-TevI. Proc Natl Acad Sci U S A 2002; 99(13):8554-61.
62. Kleinstiver BP, Wolfs JM, Kolaczyk T, Roberts AK, Hu SX, Edgell DR. Monomeric site-specific nucleases for genome editing. Proc Natl Acad Sci U S A 2012; 109(21):8061-6.
63. Arnould S, Delenda C, Grizot S, et al. The I-CreI meganuclease and its engineered derivatives: applications from cell modification to gene therapy. Protein Eng Des Sel Peds 2011; 24(1-2):27-31.
64. Pâques F, Duchateau P. Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy. Curr Gene Ther 2007; 7(1):49-66.
65. Baxter S, Lambert AR, Kuhar R, et al. Engineering domain fusion chimeras from I-OnuI family LAGLIDADG homing endonucleases. Nucleic Acids Res 2012; 40(16):7985-8000.
66. Marcaida MJ, Muñoz IG, Blanco FJ, Prieto J, Montoya G. Homing endonucleases: from basics to therapeutic applications. Cell Mol Life Sci Cmls 2010; 67(5):727-48.
67. Stoddard BL. Homing endonucleases: from microbial genetic invaders to reagents for targeted DNA modification. Structure 2011; 19(1):7-15.
68. Takeuchi R, Lambert AR, Mak AN-S. Tapping natural reservoirs of homing endonucleases for targeted gene modification. Proc Natl Acad Sci U S A 2011; 108(32):13077-82.
69. Smith J, Grizot S, Arnould S, et al. A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. Nucleic Acids Res 2006; 34(22):e149.
70. Thyme SB, Jarjour J, Takeuchi R, et al. Exploitation of binding energy for catalysis and design. Nature 2009; 461(7268):1300-4.
71. Baxter SK, Lambert AR, Scharenberg AM, Jarjour J. Flow cytometric assays for interrogating LAGLIDADG homing endonuclease DNA-binding and cleavage properties. Methods Mol Biol 2013; 978:45-61.
72. Takeuchi R, Certo M, Caprara MG, Scharenberg AM, Stoddard BL. Optimization of in vivo activity of a bifunctional homing endonuclease and maturase reverses evolutionary degradation. Nucleic Acids Res 2009; 37(3):877-90.
73. Anderson BR, Muramatsu H, Nallagatla SR, et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res 2010; 38(17):5884-92.
74. Aspden JL, Jackson RJ. Differential effects of nucleotide analogs on scanning-dependent initiation and elongation of mammalian mRNA translation in vitro. RNA 2010;16(6):1130-7.
75. Holkers M, Maggio I, Liu J, et al. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res 2013; 41(5):e63.
76. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40(2):179-204.
77. Certo MT, Gwiazda KS, Kuhar R, et al. Coupling endonucleases with DNA end-processing enzymes to drive gene disruption. Nat Methods 2012; 9(10):973-5.
78. Delacôte F, Perez C, Guyot V, et al. High frequency targeted mutagenesis using engineered endonucleases and DNA-end processing enzymes. Plos One 2013; 8(1):e53217.
79. Symington LS, Gautier J. Double-strand break end resection and repair pathway choice. Annu Rev Genet 2011; 45:247-71.
80. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461(7267):1071-8.
81. Thompson LH. Recognition, signaling, and repair of DNA doublestrand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Mutat Res 2012; 751(2):158-246.
82. Shibata A, Conrad S, Birraux J, et al. Factors determining DNA double-strand break repair pathway choice in G2 phase. EMBO J 2011; 30(6):1079-92.
83. Perez EE, Wang J, Miller JC, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008; 26(7):808-16.
84. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010; 28(8):839-47.
85. Torikai H, Reik A, Liu P-Q, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 2012; 119(24):5697-705.
86. Certo MT, Ryu BY, Annis JE, et al. Tracking genome engineering outcome at individual DNA breakpoints. Nat Methods 2011; 8(8):671-6.
87. Doyon Y, Choi VM, Xia DF, Vo TD, Gregory PD, Holmes MC. Transient cold shock enhances zinc-finger nuclease-mediated gene disruption. Nat Methods 2010; 7(6):459-60.
88. Bennardo N, Gunn A, Cheng A, Hasty P, Stark JM. Limiting the persistence of a chromosome break diminishes its mutagenic potential. Plos Genet 2009; 5(10):e1000683.
89. Simsek D, Brunet E, Wong SY-W, et al. DNA ligase III promotes alternative nonhomologous end-joining during chromosomal translocation formation. Plos Genet 2011; 7(6):e1002080.
90. Boboila C, Oksenych V, Gostissa M, et al. Robust chromosomal DNA repair via alternative end-joining in the absence of X-ray repair cross-complementing protein 1 (XRCC1). Proc Natl Acad Sci U S A 2012; 109(7):2473-8.
91. Daboussi F, Zaslavskiy M, Poirot L, et al. Chromosomal context and epigenetic mechanisms control the efficacy of genome editing by rare-cutting designer endonucleases. Nucleic Acids Res 2012; 40(13):6367-79.
92. Dreyer A-K, Cathomen T. Zinc-finger nucleases-based genome engineering to generate isogenic human cell lines. Methods Mol Biol 2012; 813:145-56.
93. Radecke F, Peter I, Radecke S, Gellhaus K, Schwarz K, Cathomen T. Targeted chromosomal gene modification in human cells by single-stranded oligodeoxynucleotides in the presence of a DNA double-strand break. Mol Ther 2006; 14(6):798-808.
94. Chen F, Pruett-Miller SM, Huang Y, et al. High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat Methods 2011; 8(9):753-5.
95. Radecke S, Radecke F, Cathomen T, Schwarz K. Zinc-finger nuclease-induced gene repair with oligodeoxynucleotides: wanted and unwanted target locus modifications. Mol Ther 2010; 18(4):743-53.
96. Delacôte F, Lopez BS. Importance of the cell cycle phase for the choice of the appropriate DSB repair pathway, for genome stability maintenance: the trans-S double-strand break repair model. Cell Cycle 2008; 7(1):33-8.
97. Delacôte F, Perez C, Guyot V, et al. Identification of genes regulating gene targeting by a high-throughput screening approach. J Nucleic Acids 2011; 2011:947212.
98. Aten JA, Stap J, Krawczyk PM, et al. Dynamics of DNA doublestrand breaks revealed by clustering of damaged chromosome domains. Science 2004; 303(5654):92-5.
99. Kobayashi J, Iwabuchi K, Miyagawa K, et al. Current topics in DNA double-strand break repair. J Radiat Res 2008; 49(2):93-103.
100. Sonoda E, Hochegger H, Saberi A, Taniguchi Y, Takeda S. Differential usage of non-homologous end-joining and homologous recombination in double strand break repair. DNA Repair 2006; 5(9/10):1021-9.
101. Rothkamm K, Krüger I, Thompson LH, Löbrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 2003; 23(16):5706-15.
102. Matthew D. Weitzman, Caroline E. Lilley, Mira S. Chaurushiya. Genomes in Conflict: Maintaining Genome Integrity During Virus Infection [Internet]. 2010 [cited 2010 Oct 6]. Available from: http://www.annualreviews.org.offcampus.lib.washington.edu/doi/full/10.1146/annurev.micro.112408.134016?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed